Premier, Inc. PINC
Premier's earnings are artificially inflated by expiring pre-IPO shareback contracts; as member hospitals renegotiate at market rates, EBITDA halves and shares fall 55-75% to $8-$15.
Thesis
Premier, Inc. (NASDAQ: PINC) is a group purchasing organization whose reported earnings are distorted by a unique 2013 pre-IPO restructuring: member-owner hospitals accepted below-market 30% sharebacks in exchange for Class B equity, roughly half what peers like Vizient/MedAssets now pay (60-75%). With most member equity already vested and the two largest members' contracts auto-renewing Oct 1, 2019 (7-year) and Oct 1, 2020 (5-year), hospitals have every incentive to demand market-rate sharebacks or defect to competing GPOs. Spruce Point cites GNYHA and Johns Hopkins' move to Vizient, accelerating Class B share dumping, and subtle 10-K language changes as evidence the cliff is near. Re-rating shareback to market would slash FY22-23 EBITDA by more than 50%, and applying a 4.5x multiple yields a $8-$15 price target, 55-75% below current levels.
SCQA
Premier is a hospital group purchasing organization generating over 50% of revenue from administrative fees, with sell-side analysts rating shares at $42.76 on the assumption that current economics are sustainable.
A 2013 pre-IPO deal locked member-owner hospitals into 30% sharebacks versus the 60-75% market rate; those five- and seven-year contracts expire starting Oct 1, 2019, and vested members now have every reason to demand market terms or exit.
Short PINC: Spruce Point recommends selling on the view that market-rate shareback resets, member defection to Vizient, and a compressed EV/EBITDA multiple will reprice the stock as contracts roll.
Base-case fair value is $10.31 per share (69.6% downside) on 57.5% shareback and 4.5x FY22 EBITDA; bear case $7.67 (-77%), with range $8-$15 implying 55-75% downside.
The three reasons
- 1
Pre-IPO deal forced members to accept 30% sharebacks vs 60-75% market rate
- 2
Two largest members' contracts auto-renew Oct 1, 2019/2020; opt-out looming
- 3
Market-rate reset would cut FY22-23 EBITDA by >50%, implying $8-$15/share
Primary demands
- Short PINC: price target $8-$15 per share (55-75% downside)
- Reassess sustainability of Premier's 30% member-owner shareback rate against the 60-75% market rate
- Recognize imminent contract renewal cliff for Premier's two largest GPO member owners on Oct 1, 2019 / 2020
KPIs cited
Pattern membership
Precedents cited
- 2U, Inc. (TWOU) - Spruce Point 2018 short where tuition take-rate normalization drove 80% decline
- MedAssets / Vizient (VHA-UHC) shareback rates post-2015 acquisition
- Johns Hopkins Medicine leaving Premier for Vizient (Apr 2019)
Composition what's on the 29 slides
Slide gallery ·
Notes
Classic Spruce Point short: mechanism-driven (contract-renewal cliff) rather than fraud allegation, though filed under fraud_exposure thesis given Spruce Point's framing that reported earnings overstate sustainable economics. Strong SCQA structure with 2U case study as analog precedent. Cover uses a macabre hospital-with-zombie-patient illustration to dramatize the 'dying' thesis. Villain is diffuse (sell-side complacency, structural contract design) rather than a named CEO. CEO-quote-contradiction flag is True based on page 5 TWOU CEO quote used to vindicate Spruce Point's prior call; Premier management's own 10-K redline (p25) is also used to expose tacit admission of cracks. Valuation framework is a scenario-based EV/EBITDA multiple comparison rather than SOTP or DCF.